Recent Updates
Recently added Catalysts

X/T+ X-EC

Phase 2

Alzheimers Disease | Small Molecules | Neurology |Bristol-Myers Squibb Company|Trials Updated: Oct 8, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment60

FDA Designations

No designations recorded

X/T+ X-EC clinical trials

X/T+ X-EC · 1 trial · 1 indication

Phase 2 1
NCT07212062The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.Alzheimers Disease
NOT YET_RECRUITING60 Analytics
PHASE2NOT YET_RECRUITING
The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.
Alzheimers DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

Assess the safety and tolerability of X/T+X-EC compared with placebo in participants with Alzheimer's Disease currently treated with Lecanemab
Baseline to week 28 as there is a 4 week follow up period after End of Treatment

Incidence of AEs/SAEs/AESIs/AEs leading to study intervention discontinuation, AEs leading to death through week 24.

Secondary Endpoints

Quality of Life in Alzheimers Disease
Three different time points from Baseline to Week 24 will be assessed.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm A- Lecanemab + X/T + X-ECACTIVE_COMPARATORParticipants will receive the active drug as well as their current Lecanemab treatment.
Arm B- Lecanemab + PlaceboPLACEBO_COMPARATORParticipants will receive the non-active drug/placebo as well as their current Lecanemab treatment.

Interventions

NameTypeDescription
X/T + X-ECDRUGXanomeline and Trospium Chloride Capsules
PlaceboDRUGPlacebo
Lecanemab 10 mg/kgDRUGParticipants will continue their current Lecanemab infusions while in the study receiving the study drug or placebo.
Unlock Study Design Details

Eligibility Criteria

Age Range60 Years to 85 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria:1. Participants or their legally acceptable representative (LAR, see Appendix 1) must be able and willing to sign and date an IRB/IEC-approved written informed consent form ICF in accordance with regulatory, local, and institutional guidelines. This ICF must be obtained before per...

Unlock Eligibility Criteria

Frequently asked questions about X/T+ X-EC

What is X/T+ X-EC?

X/T+ X-EC is an investigational small molecule being developed by Bristol-Myers Squibb Company (BMY) for Alzheimer's disease. It is in Phase 2 clinical development and is being studied in participants who are currently treated with lecanemab.

What is X/T+ X-EC used for in Alzheimer's disease?

X/T+ X-EC is being evaluated for use in Alzheimer's disease. The Phase 2 study is designed to assess its safety and tolerability in participants with Alzheimer's disease who are already receiving lecanemab treatment.

Who makes X/T+ X-EC?

X/T+ X-EC is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY.

What phase is X/T+ X-EC in?

X/T+ X-EC is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 2 trial is evaluating its safety and tolerability in Alzheimer's disease.

What clinical trials is X/T+ X-EC in?

X/T+ X-EC is being studied in one Phase 2 trial, NCT07212062, titled a study to evaluate the safety and tolerability of X/T+X-EC in participants with Alzheimer's disease who are currently treated with lecanemab. The trial is not yet recruiting and plans to enroll 60 participants.